Oncolytics' Reolysin/radiation combo elicits partial responses during phase 1 cancer trial

By Angela McDaniels

Seattle, March 3 - Oncolytics Biotech Inc. said preliminary results show that patients experienced local and systemic responses to a combination of radiation and the company's Reolysin (reovirus type 3) during a phase 1 clinical trial.

Two out of six patients treated have had significant partial responses (70% and 50%) at two and one months, respectively, after treatment and the treatment has been well tolerated, the company said.

The study's endpoints were safety, detection of viral replication, evaluation of immune response and antitumor activity.

The preliminary data is available in an abstract titled "Phase I trial of intratumoral administration of reovirus type 3 (Reolysin) in combination with radiation in patients with advanced malignancies," which can be found on the American Association for Cancer Research web site (www.aacr.org).

More detailed interim results will be presented at the American Association for Cancer Research annual meeting, which runs April 1 to 5 in Washington, D.C. The presentation will be delivered by principal investigator Kevin J. Harrington of the Cancer Research U.K. Centre for Cell and Molecular Biology.

Oncolytics is biotechnology company based in Calgary, Alta., that develops oncolytic viruses as potential cancer therapeutics.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.